AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ANIP · NASDAQ · Drug Manufacturers - Specialty & Generic

ANI Pharmaceuticals (ANIP)

Develops rare-disease therapies, niche generics, and established prescription brands.

$77.91

After hours0.00 (0.00%)

At close$77.91(−1.19%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	132	132	137	138	148	191	197	211	228	247	237	266
Cost of revenue	48	53	49	58	63	80	73	75	116	10	115	100
Gross profit	84	78	88	80	85	110	124	137	112	238	123	166
	66	72	68	75	106	115	98	123	89	189	84	125
Research & development	11	10	11	7	10	17	11	17	12	12	11	15
Selling, general & administrative	42	44	48	53	79	70	77	82	77	83	74	92
Other expenses	13	17	9	15	17	28	11	25	0	94	0	19
Operating income	18	7	20	5	−21	−4	26	14	23	48	39	40
	−6	−6	5	−7	−11	−9	−6	−3	11	−17	2	−3
Interest income	0	0	0	0	0	0	3	3	0	5	0	0
Interest expense	6	6	5	5	2	6	8	8	5	23	−4	4
Other non-operating income	0	0	−10	3	9	3	1	−2	−16	−6	2	0
Income before tax	12	1	25	−2	−31	−14	20	11	34	31	40	37
Income tax expense	2	0	7	0	−7	−3	4	2	7	4	11	12
Net income from continuing operations	10	1	18	−2	−24	−10	16	9	27	27	29	25
Other adjustments	0	0	0	0	0	0	0	0	−2	0	0	0
Net income	10	1	18	−2	−24	−10	16	9	24	27	29	25
EPS, basic	$0.50	$0.04	$0.84	−$0.14	−$1.27	−$0.55	$0.70	$0.37	$1.19	$1.24	$1.31	$1.09
EPS, diluted	$0.50	$0.04	$0.83	−$0.14	−$1.27	−$0.55	$0.69	$0.36	$1.13	$1.17	$1.28	$1.05
Weighted average shares, basic	19	19	19	19	19	19	20	20	20	20	21	21
Weighted average shares, diluted	19	19	19	19	19	19	20	20	21	21	22	22
EBITDA	33	22	45	17	−13	15	48	39	61	77	57	60
Depreciation & amortization	15	15	15	15	16	23	23	23	23	23	21	20
EBIT	18	7	30	2	−29	−8	25	16	39	54	36	41